Immunotherapy works for sepsis thanks to smart patient selection
Peer-Reviewed Publication
Updates every hour. Last Updated: 27-Dec-2025 14:11 ET (27-Dec-2025 19:11 GMT/UTC)
Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient’s immune system condition. While earlier research showed little benefit of immunotherapy in sepsis, a new study demonstrates that a targeted approach of immunotherapy does improve clinical outcomes. This is reported by a consortium of 33 hospitals in JAMA, led by Radboud university medical center and the Hellenic Institute for the Study of Sepsis.
New evidence from a six-country study led by the Montreal Children’s Hospital and Children’s National Hospital shows simple blood and urine tests could spare many young infants with fevers from more invasive procedures.
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using the T-Charge™ platform, show a manageable safety profile and antitumor activity.
With a four-year, $3.2 million grant from the National Institutes of Health, a team from Pen State College of Medicine will develop a small, durable ventricular assist device (VAD) designed specifically for young, growing children between the ages of one and 11 years old. Currently, there are no heart pumps approved for long-term use for this age group. The device, called the PSU Child VAD, could provide long-term support for children with heart failure while waiting for a heart transplant, greatly improving quality of life and outcomes.